Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, and Herceptin in Patients With Metastatic Breast Cancer.

Trial Profile

A Phase I Dose Escalation Study of the Safety and Tolerability of Lapatinib in Combination With Carboplatin, Paclitaxel, and Herceptin in Patients With Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs Lapatinib (Primary) ; Carboplatin; Paclitaxel; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
  • Most Recent Events

    • 21 Dec 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 06 Jun 2017 Planned End Date changed from 21 Dec 2017 to 31 Dec 2018.
    • 06 Jun 2017 Planned primary completion date changed from 21 Dec 2017 to 31 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top